Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-16 of 16 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

Immunotherapy for advanced or metastatic urothelial carcinoma.
Maisch P, Hwang EC, Kim K, Narayan VM, Bakker C, Kunath F, Dahm P
Cochrane Database Syst Rev, 10:CD013774, 09 Oct 2023
Cited by: 3 articles | PMID: 37811690 | PMCID: PMC10561349
Add to export list Review Free full text in Europe PMC
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.
Wang Y, Zhou Y, Yang L, Lei L, He B, Cao J, Gao H
Adv Sci (Weinh), 11(1):e2303175, 07 Nov 2023
Cited by: 10 articles | PMID: 37934012 | PMCID: PMC10767451
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.
Olah C, Reis H, Hoffmann MJ, Mairinger F, Ting S, Hadaschik B, Krafft U, Grünwald V, Nyirady P, Varadi M, Győrffy B, Kiss A, Szekely E, Sjödahl G, Szarvas T
Cancer Med, 12(5):5222-5232, 07 Oct 2022
Cited by: 3 articles | PMID: 36204983 | PMCID: PMC10028049
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.
Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y, Katsumata H, Sato Y, Iwamura M
Int J Mol Sci, 23(20):12119, 11 Oct 2022
Cited by: 2 articles | PMID: 36292976 | PMCID: PMC9602626
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature.
Dello Russo C, Navarra P
Front Pharmacol, 13:858354, 16 May 2022
Cited by: 2 articles | PMID: 35652050 | PMCID: PMC9149259
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach.
Mancini M, Righetto M, Noessner E
Cancers (Basel), 13(23):6016, 29 Nov 2021
Cited by: 20 articles | PMID: 34885126 | PMCID: PMC8656785
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Bamias A, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN
ESMO Open, 6(3):100152, 10 May 2021
Cited by: 4 articles | PMID: 33984672 | PMCID: PMC8134736
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Coming of Age of Immunotherapy of Urothelial Cancer.
Grande E, Molina-Cerrillo J, Necchi A
Target Oncol, 16(3):283-294, 12 Mar 2021
Cited by: 1 article | PMID: 33710533
Add to export list Review
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Börcsök J, Diossy M, Sztupinszki Z, Prosz A, Tisza V, Spisak S, Rusz O, Stormoen DR, Pappot H, Csabai I, Brunak S, Mouw KW, Szallasi Z
Clin Cancer Res, 27(13):3734-3743, 04 May 2021
Cited by: 13 articles | PMID: 33947694 | PMCID: PMC8896908
Add to export list Free full text in Europe PMC
Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials.
Li Z, Li X, Lam W, Cao Y, Han H, Zhang X, Fang J, Xiao K, Zhou F
Front Oncol, 11:629646, 01 Apr 2021
Cited by: 2 articles | PMID: 33869015 | PMCID: PMC8047637
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.
Huang J, Teng X
Curr Oncol, 27(6):e656-e663, 01 Dec 2020
Cited by: 9 articles | PMID: 33380881 | PMCID: PMC7755433
Add to export list Review Free full text in Europe PMC
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J, Sztupinszki Z, Bekele R, Gao SP, Diossy M, Samant AS, Dillon KM, Tisza V, Spisák S, Rusz O, Csabai I, Pappot H, Frazier ZJ, Konieczkowski DJ, Liu D, Vasani N, Rodrigues JA, Solit DB, Hoffman-Censits JH, [...] Szallasi Z
Clin Cancer Res, 27(7):2011-2022, 18 Nov 2020
Cited by: 17 articles | PMID: 33208343 | PMCID: PMC8026514
Add to export list Free full text in Europe PMC
Consultation on UTUC, Stockholm 2018: aspects of treatment.
Jung H, Giusti G, Fajkovic H, Herrmann T, Jones R, Straub M, Baard J, Osther PJS, Brehmer M
World J Urol, 37(11):2279-2287, 23 May 2019
Cited by: 12 articles | PMID: 31123852 | PMCID: PMC6825640
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Yoo B, Jordan VC, Sheedy P, Billig AM, Ross A, Pantazopoulos P, Medarova Z
Sci Rep, 9(1):4712, 18 Mar 2019
Cited by: 25 articles | PMID: 30886310 | PMCID: PMC6423142
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
Nakamura Y
Front Med (Lausanne), 6:119, 29 May 2019
Cited by: 90 articles | PMID: 31192215 | PMCID: PMC6549005
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination.
Sapalidis K, Zarogoulidis P, Pavlidis E, Laskou S, Katsaounis A, Koulouris C, Giannakidis D, Mantalovas S, Huang H, Bai C, Wen Y, Wang L, Sardeli C, Amaniti A, Karapantzos I, Karapantzou C, Hohenforst-Schmidt W, Konstantinou F, Kesisoglou I, Benhanseen N
J Cancer, 9(11):1973-1977, 30 Apr 2018
Cited by: 2 articles | PMID: 29896282 | PMCID: PMC5995940
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-16 of 16 results

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Immunotherapy for advanced or metastatic urothelial carcinoma.

Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.

Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.

Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature.

Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach.

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

Coming of Age of Immunotherapy of Urothelial Cancer.

Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials.

Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.

Consultation on UTUC, Stockholm 2018: aspects of treatment.

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination.

Partnerships & funding